Constellation Brings In Series B Totaling $22 Million, Including GSK Investment
This article was originally published in The Pink Sheet Daily
Executive Summary
Involvement by GSK's venture arm SR One enables Constellation to keep pace with epigenetics competitor Epizyme, which is backed by Amgen and Astellas.